MedTrace Logo

Nutrition in Gastroenteropancreatic Neuroendocrine Tumor

NCT04986085 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 399

Last updated 2025-03-28

Study results available
· View outcomes & findings →

Summary

It is well known that the prevalence of malnutrition or risk of malnutrition in cancer patients is high, as well as its impact on different parameters such as hospitalization, survival or response to certain treatments. In patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET), due to their heterogeneity and longer survival, it is expected that the prevalence of malnutrition is probably underdiagnosed, as well as the existence of a negative impact on different parameters (quality of life, survival). So far, the studies carried out on nutrition and NET are very scarce and none has been carried out so far in Spain.

Before being able to carry out nutritional intervention studies on these patients, it is necessary to know the reality of the nutritional status of patients with NETs in Spain. The main motivation for the NUTRIGETNE study is to evaluate the epidemiological status of nutrition in NETs in the spanish population. In addition to know the epidemiological picture, it is intended to study the nutritional status from different points of view: analytical, clinical, anthropometric, etc. Besides, the study of nutritional status will allow us to closely monitor the patients who have a higher risk of malnutrition and to propose early interventions for those, as well as the impact of their nutritional status on different parameters: survival, hospitalization, quality of life or responses to the treatments.

NUTRIGETNE is a cross-sectional, open and multicenter study in which the nutritional status of patients with GEP NET in Spain will be evaluated.

Conditions

  • Gastroenteropancreatic Neuroendocrine Tumor

Sponsors & Collaborators

  • Grupo Espanol de Tumores Neuroendocrinos

    lead OTHER

Principal Investigators

  • María Isabel del Olmo García, M.D. Ph.D. · Hospital Universitario La Fe

  • María Argente Pla, M.D. Ph.D. · Hospital Universitario La Fe

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-24
Primary Completion
2024-01-23
Completion
2024-02-23

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04986085 on ClinicalTrials.gov